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effect was the least important attribute in both datasets, the relative importance of 
the other attributes differed. All results differed by educational level. Estimated and 
observed choices showed higher correlation in the word dataset. ConClusions: 
The presentation of the choice tasks by either using words or graphics influences 
study outcomes. The use of graphics to present attribute levels in choice tasks seems 
less preferred by respondents and showed a reduced validity. Besides extensive pilot 
testing, discussions about the presentation of the choice tasks should be included in 
the focus group stage of the designing process. Extensive research on respondents’ 
interpretation of choice tasks should be conducted to enable the formation of choice 
task presentation guidelines.
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SiMilaRitieS and diffeRenceS acRoSS SaMe language QueStionnaiReS 
foR diffeRent countRieS: linguiStic Validation of the aSthMa 
SyMPtoM diaRy (aSd) and Kidney diSeaSe and Quality of life  
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objeCtives: Prior to use in an international study, the Asthma Symptom Diary 
and Kidney Disease and Quality of Life underwent linguistic validation into over 
30 languages. This involved linguistic validation work on common languages tar-
geted for different countries via the forward / backward translations or adaptation 
steps and cognitive debriefing step. This study aims to investigate similarities and 
differences in the translation of key terms and wordings and determine potential 
patterns across groups of languages. Methods: This investigation was carried out 
as follows: 1) Identification of key terms and words; 2) Collation and comparison of 
the translations across the same language versions; 3) Identification of similarities 
and differences; and 4) Review of discussions and issues from the translation pro-
cess. Results: The linguistic validation process was shown to be able to identify and 
resolve important cross-cultural differences. Key findings included the identifica-
tion of potential recurring translation issues between same language groups. Within 
the German, French and Spanish languages, technical terminology was translated 
alike whilst there were differences in the way non-technical, socially constructed 
wordings, emotions and symptoms were translated due to such factors as idiomatic 
formulations and cultural differences. Across the English languages, the text was 
simplified or elaborated as part of the adaptation process. Across the Russian and 
Chinese languages there were differences in the way technical and disease-specific 
terms were translated. ConClusions: With the insight of the linguistic validation 
process, important differences were identified and resolved between technical terms 
and general wordings across same language groups. Cognitive debriefing is highly 
recommended and this will ensure appropriate comprehension across cultures and 
facilitate International comparison and pooling of data.
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objeCtives: Photoguides are used as measures of treatment effect. To interpret 
the results, an understanding of what change is “enough” is required. The purpose 
of this study was to determine the Patient Detectable Difference (PDD) and Patient 
Relevant Difference (PRD) in scar severity using a discrete choice experiment with 
paired comparisons of scar photos via the internet. Methods: Patients were asked 
to select the scar most like their own from a 5-photo photoguide as the referent. 
Each patient was then presented with a randomly selected scar from a scar library 
previously scored on severity by clinicians. For the PDD, patients were asked if the 
random scar was better, worse, or about the same. For the PRD, patients were asked 
if they would undergo treatment to “get” the random scar as opposed to keeping 
the referent scar. Each exercise was repeated five times. Optimal cutoff scores for 
PDD and PRD were based on a random intercept logistic model (RILM). Results: 
Using a series of RILM estimations across 514 participants, the PDD was calcu-
lated as 15.4 points on a 100-point scale (area under curve = 0.85, sensitivity = 
0.83, specificity = 0.73). In subgroup analyses by gender and scar source, the PDD 
ranged from 9.5 to 22.0 points. The replicate analysis adjusting for directionality 
of preference (improvement only) showed a PRD of 26.9 points (area under curve 
= 0.97, sensitivity = 0.90, specificity = 0.93), which ranged from 19.5 to 32.0 in the 
subgroups. ConClusions: Results show that, as expected, scar patients report 
detectable differences in scar severity that are smaller than what they report as 
relevant differences necessary to choose treatment. The Internet-based approach 
using a discrete choice experiment is a novel method to quantify the threshold of 
detectable and relevant differences in scar severity using a photoguide.
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objeCtives: Advances in understanding the neural underpinnings of intellectual 
disabilities (ID) such as fragile X syndrome (FXS) have led to clinical trials testing 
medications addressing disease-specific targets. Individuals with ID ought to have 
a voice in consenting for clinical trials, but the extent to which they are capable 
of doing so is unknown. We discuss the importance of involving individuals with 
ID in the consent process and report results from a study of parents’ perceptions 
of their child’s ability to consent. Methods: A survey was conducted with 422 
families who had a child with FXS. Parents rated items assessing their child’s abil-
ing cognitive interviews during the linguistic validation process of COAs. Further 
research is required to develop industry guidelines to ensure that the interviews 
are able to achieve their purpose: garnering accurate and meaningful feedback from 
respondents in order to increase comprehension and cross-cultural equivalence of 
multiple language versions.
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objeCtives: As the linguistic validation of COA instruments often includes a review 
of medical terminology, it is important to confirm that the in-country clinician 
reviewer has sufficient qualifications to ensure quality as well as to elicit the highest 
level of conceptual equivalence in a linguistic validation project. This poster will 
consider each type of COA (Clinical Outcomes Assessment) and recommend guide-
lines for the qualifications of medical reviewers. Methods: An examination was 
conducted of past linguistic validation projects involving an in-country review step 
with a medical professional. A review was completed of COAs (Clinician-Reported, 
Caregiver-Reported, as well as Patient-Reported questionnaires and diaries) within 
various therapeutic areas. This review also included an analysis of the specific 
background of each in-country clinician reviewer. Results: In the examination 
of linguistic validation projects that included a medical review step, it was deter-
mined that the experience level of clinician reviewers varied between projects. 
In an effort to standardize this step, a minimum experience requirement based 
on study needs and project type is proposed. ConClusions: After a thorough 
review of past linguistic validation projects, it is suggested that an in-county clini-
cian reviewer should, at a minimum, encompass the following qualifications: 1) 
2+ years experience diagnosing and/or treating the patient population; 2) M.D. or 
relevant equivalent in the target country; 3) Native-language and/or advanced medi-
cal terminology training in the target language/country. Implementing minimum 
qualifications standards will help to ensure that an in-country medical reviewer 
will conduct a high-quality review for linguistically validated COAs.
PRM159
eValuation of the PSoRiaSiS aRea and SeVeRity indeX (PaSi) aS Patient 
ReleVant outcoMe in the Benefit aSSeSSMent of PSoRiaSiS theRaPieS
Gutknecht M., Augustin M., Rustenbach S.J., Schäfer I.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
objeCtives: Psoriasis vulgaris is one of the most frequent chronic diseases in der-
matology and can cause a high disease burden and reduction of quality of life. The 
severity of psoriasis is determined by the clinical parameter PASI (Psoriasis Area and 
Severity Index). It is the most often cited measurement to determine the efficacy of 
therapies. Since the assessment of patient relevant treatment benefit gains impor-
tance in treatment evaluation, the objective of the study was to test to what extent 
PASI improvements agree with patient relevant benefit parameter. Methods: A 
multicenter longitudinal observational study was conducted in n = 218 patients with 
psoriasis vulgaris. Data collection took place at the beginning of psoriasis treatment 
and between three and eight weeks after treatment. In addition to PASI, physician 
and patient data were collected, e.g. socio-demographics, clinical features, derma-
tological quality of life (DLQI), and assessment of treatment. Results: Each level of 
PASI (50, 75, 90) showed relevant improvements in patient reported outcomes. The 
satisfaction with the treatment and the patient benefit was greater, the higher PASI 
was reached. This effect was not seen for DLQI. However, improvements were only 
significant for PBI for all levels of PASI. Furthermore, results showed that not only 
changes in PASI but also its absolute value at the end of treatment has an impact for 
the patient reported assessment of therapy. Values < 3 in comparison to < 5 resulted 
in better values of PBI and higher treatment satisfaction. ConClusions: The clini-
cal reduction of the severity of psoriasis vulgaris correlates with the improvement 
of the quality of life and with the patient defined treatment benefit. However, the 
PASI does not completely reflect the patient relevant outcome in the benefit assess-
ment. Therefore, it is recommended to make additional elicitation of patient defined 
objectives and benefits in the evaluation of psoriasis therapies.
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objeCtives: To test to what extent the presentation of choice tasks contrasting 
display in words or graphics, influences the attribute estimates, relative importance 
and participation probability and the conclusions drawn from a Discrete Choice 
Experiment (DCE). Methods: A DCE questionnaire was sent to the parents of 
2,500 newborn babies aged 6 weeks at maximum. Each questionnaire contained 
two versions of the same 9 choice tasks, one in which the levels were presented in 
words, and one with graphic attribute levels. The DCE consisted of five attributes: 
vaccine effectiveness, frequency of severe side effects, protection duration, location 
of vaccine administration, out-of-pocket costs. Choice consistency was estimated, 
panel-mixed logit models were conducted to estimate the relative importance of 
the attributes and internal sample validation was calculated. Results: In total 13% 
answered consistent on all choice tasks, 19% answered inconsistently in one choice 
task, and 51% answered inconsistently in more than two choice tasks. Respondents 
who were presented with word choice tasks at first were significantly more consist-
ent compared to respondents that were presented with graphic choice tasks at first. 
Although out-of-pocket costs was the most important and frequency of severe side 
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the two scales on different patients can be compared or integrated across stud-
ies. Methods: Data were taken from the 2011 and 2012 US National Health and 
Wellness Survey (NHWS). The NHWS is a large cross-sectional survey representative 
of the total adult population in several major markets; current analyses were limited 
to the US (n~75,000/year). Respondents self-reported physician diagnosis of various 
health conditions, including 9,633 who reported a diagnosis of IBS. Adherence was 
measured with MMAS-4 in 2011 and MMAS-8 in 2012. The two adherence scales 
were evaluated by comparing the frequency distributions of the MMAS scores in the 
two scales, Cronbach’s alpha and inter-item correlations, and the creation of a new 
4-item scale including the questions in MMAS-8 that best matched the questions 
in MMAS-4. Results: In IBS patients, both MMAS-4 and -8 scores are Poisson-like 
distributed, with median at zero (high adherence). Chronbach’s alpha was 0.64 for 
MMAS-4 and 0.70 for MMAS-8, while average item-test correlations were 0.70 and 
0.59, respectively. The reduced 4-item scale created out of MMAS-8 is also Poisson-
like distributed, Cronbach’s alpha was 0.67 and the average item-test correlation was 
0.71. ConClusions: Data obtained with the two MMAS show similar qualitative 
and quantitative characteristics, suggesting that it may be appropriate to integrate 
data sources using the two different versions, particularly when the responses to 
the subset of 4 MMAS-8 items are available. Future research should confirm that 
the scales can be integrated in different therapeutic areas.
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objeCtives: Many instruments used to assess outcomes of treatment for Alzheimer’s 
disease (AD) have no published evidence for their content validity in mild cognitive 
impairment (MCI) or prodromal AD (pAD). The objective of this project was to evalu-
ate the content validity of AD patient reported outcome (PRO) instruments in this 
population. Methods: Two waves of interviews were conducted: First, 11 patients 
with MCI and their informants/ (carers) evaluated several AD PROs (Alzheimer’s 
Disease Medication Administration Questionnaire (ADMAQ), Abbreviated Resource 
Utilization in Dementia-Lite (RUD-Lite), Perceived Deficits Questionnaire (PDQ), and 
Abbreviated Dependence Scale (AB DS); Second, 8 patients with pAD reviewed the 
modified PDQ, and their carers reviewed the RUD Lite. Interviews were transcribed 
and analysed. Results: Results of Wave 1 identified the PDQ and the RUD-Lite as 
the most promising measures for this cohort. Some minor modifications were sug-
gested for the PDQ, and a separate section was added to the RUD-Lite. Results of Wave 
2 showed pAD carers viewed the content of the RUD- Lite as less relevant because 
the patients are not functionally restricted enough to utilize resources at this early 
stage of the disease, although the newly added domain for the pAD population was 
understood and applicable. The modified PDQ was more acceptable to pAD patients 
than the original version. ConClusions: Even well-established measures for AD 
patients should have their content validity evaluated prior to their use in pAD or MCI 
populations. In this study, we found that the PDQ and RUD –Lite needed modifications 
to be more relevant in early stage patients.
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objeCtives: Timeline and budget considerations for the linguistic validation of 
Clinical Outcome Assessments (COAs) can vary substantially depending on patient 
population requirements and target locales. Rare diagnoses and/or small popula-
tions of native speakers of a language can lead to a small pool of eligible patients 
for cognitive debriefing respondents. This review highlights considerations neces-
sary to promote successful linguistic validation projects and mitigate the potential 
impact of small patient populations that, in turn, can affect study timelines as a 
whole. Methods: To assess possible steps to take during study planning and the 
linguistic validation process, a literature review and examination of past linguistic 
validation projects were completed. This focused on trials in which a small patient 
population limited the number of eligible cognitive interviewing respondents, and 
the issues and solutions associated with each project. Results: In order to meet 
timeline and budget requirements, it is crucial that sufficient steps are taken to 
ensure cognitive interviewing populations are fully evaluated during a trial’s plan-
ning stages. Solutions for helping achieve this include: 1) Identification and possible 
inclusion of broader patient populations with conditions with similar symptoms; 2) 
Extended timeline consideration for rare diseases or small native-speaking popula-
tions at study start; 3) Selection of more general COAs (e.g. not specific to the diag-
nosis in the case of rare conditions) so cognitive interviewing may be performed on 
healthy respondents or a broader group of patients. ConClusions: When choosing 
COAs for global use, an analysis of the intended patient population – including 
prevalence rates of the condition and size of the native-speaking population – is 
recommended in order to integrate projected linguistic validation timelines into 
the overall study plan. It is also recommended that study teams discuss this with 
their language services team for guidance on timelines and assistance in planning 
to ensure targeted study milestones are met.
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ity to understand and complete six consent tasks. They also provided information 
about themselves (maternal education, willingness to enroll child in a clinical trial) 
and their child (age, autism status, thinking/reasoning ability, gender). Results: 
Factor analysis confirmed that the six items comprise a single factor. However, we 
found a clear hierarchy of difficulty; the least difficult tasks were “understands that 
this medication is different from his/her regular treatment” and “realizes that he/
she can choose to participate in the study or withdraw at any time.” The most dif-
ficult were “can make a decision about study participation” and “understands and 
weighs potential benefits and risks of participating in the study.” Although 29% of 
parents reported that their son was not at all capable of participating, the remainder 
exhibited a range of decisional skills. Factors associated with this variability include 
gender, autism, cognitive ability, age, and parents’ willingness to enroll their child 
in clinical trials. ConClusions: Parents rate many individuals with FXS as able to 
participate in the consent process, but they will likely need support to maximize 
effective participation. We conclude with a brief review of strategies to support more 
inclusive participation in the consent process for people with ID.
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objeCtives: Primary objective of the Percepolis study was to look at patient’s percep-
tion regarding their Erythropoiesis Stimulating Agents (ESA) treatment of anemia in 
chronic kidney disease. Many discussions arose at the set-up of the study regarding 
the best collection method of PROs as target population was old. The following fac-
tors helped to make a decision towards ePRO: - Clinical data were collected using 
an eCRF and previous experience of studies using PROs showed it was difficult to 
mix method of collecting data, - PRO was the primary endpoint of this study and 
needed to be carefully monitored, - Most elderly people use new technologies (cellular 
phone, PC), - Twenty questionnaires needed to be equally distributed. Methods: 
This is a 6-month multicenter prospective Non-Interventional Study (NIS). Patients 
had to complete questionnaires at baseline and around 6-month in order to analyze 
the importance they gave to their ESA treatment characteristics. Technology used 
was the Tablet PC Samsung Galaxy Tab and specific interface was developed on the 
Operating System (O.S.) Android to maximize ease of use of the device for patients 
and investigators. For example, patients only had to select an answer on the screen 
to display the next question using the tactile functionnalities of the device. When 
connecting to the electronic data capture system, O.S. was detected in order to fit the 
screen’s display of the HTML pages. Results: A total of 789 patients were included, 
93% patients answered at least one questionnaire at baseline, 87% after 6 months 
of treatment. Mean age of the study population was 73 years old (± 13 years). Most 
PROs (95%) were answered using the Tablet PC. ConClusions: ePROs can be used in 
elderly population as long as tools are adequately developed to simplify use of devices. 
ePROs also allowed following online study recruitment and questionnaires data entry.
PRM164
how BuRdenSoMe iS coMPletion of electRonic Patient-RePoRted 
outcoMeS (ePRo)? iteM coMPletion tiMeS and QualitatiVe eVidence 
fRoM StudieS in fouR diffeRent health conditionS
Arbuckle R.1, Tolley C.1, Burbridge C.2
1Adelphi Values, Bollington, UK, 2Pfizer Ltd., Surrey, UK
objeCtives: The patient burden of completing large numbers of patient-reported 
outcome (PRO) items is often a concern; particularly when PROs must be completed 
daily, or at multiple timepoints over long studies. However, as ePRO and mPRO 
(technology that utilizes patients’ personal tablets and smartphones) methods 
advance, PRO completion becomes quicker and easier. How long does it actually 
take patients to complete ePROs? How burdensome do patients find ePRO comple-
tion? Methods: ePRO allows collection of the time taken to complete a set of PRO 
items. We summarise data from four qualitative studies across a range of health 
conditions (fibromyalgia, a women’s health condition, pediatric constipation and 
pediatric irritable bowel syndrome). In all four studies, small samples of patients 
(n= 20-65) completed an ePRO diary daily for 5-9 days during pilot testing prior to 
cognitive debriefing. Completion times and missed days were collected. During 
the cognitive debriefing interviews patients were asked how burdensome the PRO 
completion was and if they had difficulty fitting it into their daily routine. Results: 
The PROs being developed had 15-35 items, but two included skip patterns, reducing 
the item burden. Average completion times ranged from 2.5-5.5 minutes per diary. 
For diaries without skip patterns, mean ‘per item’ completion times were calculated 
to range from 9.4-15.7 seconds. The majority of patients (93-100%) reported that the 
PRO was quick and easy to complete and not burdensome. Missed diary rates were 
consistently low with only 0-12% of patients missing more than one diary comple-
tion in the two studies where this information was collected. ConClusions: These 
data provide evidence that patients (including children) can complete ePRO diaries 
very quickly, don’t find this burdensome, and are happy to complete relatively large 
numbers of items daily. If ePROs are carefully designed, using skip-patterns and 
event driven items, completion burden can be reduced even further.
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objeCtives: The 4-item Morisky Medication Adherence Scale (MMAS-4) and the 
more recent 8-item version (MMAS-8) have been both validated, and their concur-
rent validity has been assessed among hypertensive patients, but the extent to 
which the two scales can be compared against one another has not been deter-
mined. The current analysis assessed whether adherence scores obtained with 
